In recent years, the process of the programmed cell death has gained much interest because it has important pathophysiological consequences contributing to the deletion of unwanted cells in the vessel wall, loss of pulmonary smooth muscle cells and therefore in reversing the pulmonary pressure. For the reason that most patients with pulmonary hypertension present with limited reversibility with vasodilators, antiremodeling approach for treatment appears to be feasible. Induction or enhancement of vascular smooth muscle cells apoptosis may be targeted to develop novel therapeutic approaches for pulmonary vascular remodeling in patients with pulmonary hypertension. This review summarizes the current mechanisms, investigate the roles and provide novel insights into the potential therapeutic value of apoptosis in the pulmonary artery remodeling of pulmonary hypertension. #
Pulmonary artery hypertension overview
Pulmonary arterial hypertension (PAH) is a severe disease with poor prognosis, caused by vasoconstriction, in situ thrombosis and vascular remodeling of small pulmonary arteries inducing a fixed pulmonary arterial obstruction and persistent elevation of pulmonary arterial resistance.
Pulmonary arterial hypertension can be classified into two categories: (1) primary and (2) secondary. Primary pulmonary hypertension (familial and sporadic) is relatively severe and rare. Secondary pulmonary hypertension (SPH), whether from parenchymal lung disease or other etiologies, is more common than primary pulmonary hypertension (PPH). However, both the primary and secondary pulmonary hypertension has identical pathologic features, a similar clinical course [1] .
Pulmonary hypertension (PHT) is a progressive and oftenfatal disease for which there is little effective treatment at present [2] . Without treatment, the disorder progresses in most cases to right heart failure and death. One of the difficulties in treating patients with PAH is that the subacute nature of disease presentation often prevents an accurate diagnosis during the early stages of the illness. Conventional treatment consists of lifetime administration of anticoagulants, oxygen, diuretics, and digoxin. Vasodilator therapy with calcium channel antagonists is indicated in patients who are 'vasoreactive' to acute vasodilator challenge as assessed by right-heart catheterisation. Promising results are obtained by continuous intravenous administration of epoprostenol (prostacyclin). Newer therapies for PPH include prostacyclin analogues, endothelin receptor antagonists, nitric oxide, phosphodiesterase-5 inhibitors, elastase inhibitors, and gene therapy. With current therapies progression of disease is slowed, but not halted. Lung transplantation remains the only treatment option for patients with uncontrollable pulmonary hypertension.
Pathophysiology and pathogenesis of pulmonary hypertension
Pulmonary arterial hypertension is a disease of the small pulmonary arteries in which the combined effects of pulmonary artery vasoconstriction, vascular remodeling and thrombosis greatly contribute to a sustained elevation of pulmonary vascular resistance (PVR) and pulmonary www.elsevier.com/locate/ejcts European Journal of Cardio-thoracic Surgery 30 (2006) [499] [500] [501] [502] [503] [504] [505] [506] [507] arterial pressure (PAP) in patients with pulmonary arterial hypertension (PAH) [3, 4] . The pathogenesis of pulmonary arterial hypertension is a complicated, multifactorial process ( Fig. 1) . Although growth is the mechanism that is more classically associated with vascular remodeling, it has increasingly been appreciated that apoptosis, lowgrade inflammation, and vascular fibrosis are dynamic processes that also may influence the degree of remodeling that occurs [5] . It is notable that tissue remodeling also involves apoptosis to counteract the effects of proliferation. The role and therapeutic value of apoptosis in pulmonary hypertension will be prominently discussed below.
Vascular remodeling
Remodeling is frequently used to describe any structural and functional alteration of blood vessels that would allow them to perform their function more effectively. Remodeling is usually an adaptive process in response to long-term changes in hemodynamic conditions, as occurs during development, but it can also contribute to the pathophysiology of vascular diseases and circulatory disorders. Remodeling may be classified based on the: (1) nature of changes in vessel luminal diameter as vessel enlargement (outward remodeling), vessel narrowing (inward remodeling), alternatively as adaptive (compensatory, appropriate to the hemodynamic stimulus), or maladaptive (dysfunctional, inappropriate); (2) alterations of tunica media mass (increased = hypertrophic, decreased = atrophic, no change = eutrophic) [6] . As an example 'hypertrophic inward' remodeling would be defined as a decrease in lumen diameter with increased wall thickness such as may occur with increased pressure. It has been best studied in resistance vessels during hypertension (Fig. 2) . However, varied forms of remodeling frequently may coexist in different vascular beds of the same individual.
Cellular processes underlying events in remodeling include altered vascular smooth muscle cell (VSMC) growth, migration, differentiation and increased extracellular matrix abundance. Artery wall remodeling is a hallmark of severe, advanced pulmonary hypertension, presenting histologically as neointimal proliferation, intimal fibrosis, medial and adventitial hyperplasia and hypertrophy. Neomuscularisation of non-muscular arteries and formation of plexiform and neointimal lesions also occur [7] [8] [9] . It is accompanied by remodeling of the extracellular matrix (ECM) by proteinases [10, 11] and by increased expression and deposition of the ECM components elastin, collagen [12, 13] fibronectin [14, 15] and tenascin-C (TN) [15, 16] . Subsequent intimal thickening, fibrosis and in situ thrombosis, altogether lead to vasoocclusive alterations referred to as plexiform lesions.
Impact of remodeling on hypertension
Pulmonary vascular remodeling can be initiated by a variety of stimuli, including chronic hypoxia, increased Fig. 1 . Pathophysiologic mechanisms in PAH. Combined effects of pulmonary artery vasoconstriction, vascular remodeling and thrombosis leading to a sustained elevation of pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP) in PAH. Vascular remodeling involves all the sheaths of the vessel wall and all the cell types of which it is composed (endothelial cells, smooth muscle cells, fibroblasts, inflammatory cells and platelets). Growth, apoptosis, low-grade inflammation, ions and vascular fibrosis are dynamic processes that all may influence the degree of remodeling that occur. Excessive vasoconstriction has been related to a defect in the function of expression of the potassium channels and endothelial dysfunction. This leads to chronic insufficiency in the production of vasodilators, notably nitrogen monoxide and prostacyclin and the excessive production of vasoconstrictors such as endotheline-1. pulmonary blood flow, collagen vascular disease, anorectic and other drugs, and idiopathic causes. As the major component of the vascular media, pulmonary artery smooth muscle cells (PASMC) are the main effectors of the physiological response(s) induced during this process [17, 18] . Moreover, the degree of the structural alteration of the lung vessels varies between species [19] .
It is still a matter of debate whether the structural changes of blood vessels precede hypertension and are thus involved in its pathogenesis to some degree or whether they result from the elevation of blood pressure [20] [21] [22] . Pulmonary vascular remodeling is leading to increased pulmonary vascular resistance and reduced compliance. This tendency of peripheral vascular beds to increase flow resistance for a given increase of bulk flow or driving pressure may amplify and stabilize blood pressure elevation in the development of hypertension. At the same time microvasculature is an extremely adaptable structure, made up of cellular and noncellular components, that is capable of architectural and functional adjustments in response to multiple biochemical and mechanical stimuli, in which their diameters and wall thicknesses change in response to chronic changes in hemodynamic conditions (as a reduced lumen diameter and consequent increased media:lumen ratio). Inadequate or inappropriate adjustments often result in pathophysiology [23] .
As it has been mentioned before, vascular remodeling is an adaptive response to variations in the hemodynamic environment acting on the arterial wall. The structure of blood vessels is not constant but is continually being adjusted to allow them to fulfil their function of delivering blood to the capillaries in the correct quantity and at the correct pressure [24] . At the acute stage, increased neurohumoral activity leads to vasoconstriction and increases blood pressure. Although vasomotor control allows rapid adaptation of lumen diameter, vascular remodeling constitutes an active process that occurs in response to longterm alterations of hemodynamic parameters. In the long run, the increased pressure will be maintained by a normal neurohumoral drive but with an increased wall:lumen ratio, in other words, the situation normally seen in hypertension. To withstand the chronic increase in intraluminal pressure, the vessel wall becomes thickened and stronger. This 'armouring' of the vessel wall with extra-smooth muscle and extracellular matrix leads to a decrease in lumen diameter and reduced capacity for vasodilatation. Remodeling of small arteries may increase vascular resistance even at full dilatation, i.e., in the absence of vascular tone [20] . Resulting remodeling of these arteries may initially be adaptive, but eventually it becomes maladaptive and compromises organ function, contributing to the pathology of vascular diseases and cardiovascular complications of hypertension [20, 23] . The maladaptive response results in an inappropriate increased pulmonary vascular resistance and consequently, sustained pulmonary hypertension. Severe pulmonary hypertension increases right ventricular afterload and eventually leads to the clinical syndrome of right heart failure with systemic congestion and inability to adapt right ventricular output to peripheral demand [25] . Increased awareness of vascular remodeling may provide new therapeutic insights for the future.
Vasoconstriction and thrombosis
Excessive vasoconstriction has been related to a defect in the function of expression of the potassium channels and endothelial dysfunction [26] . Endothelial dysfunction leads to chronic insufficiency in the production of vasodilators, notably nitric oxide and prostacyclin and the excessive production of vasoconstrictors such as endothelin (ET)-1. Vascular thrombosis, which has been noted by pathologists in pulmonary hypertension, could be related to an imbalance between thrombotic inducing factors (such as anti-phospholipid antibodies, ET-1 and thromboxane) and decreased fibrinolytic activity and antiaggregant endothelial factors (like prostacyclin, NO, thrombomodulin) [27] . Thus, vasoconstriction and thrombosis contribute to the increase in vascular tonus and pulmonary vascular remodeling. Chronic vasoconstriction may result in an inwardly remodeled blood vessel as the contracted vessel structure becomes embedded in a remodeled extracellular matrix, further promoting rearrangement of SMCs around a smaller lumen.
Until now, the pathogenesis of pulmonary hypertension is still not fully understood. Abnormalities in the homeostasis of intracellular Ca (2+), transmembrane flux of ions, and membrane potential may play significant roles in the processes leading to pulmonary vascular remodeling. The inhibition of Kv channels results in an accumulation of positively charged K + ions within the cell, raising the membrane potential to more positive levels (depolarization), which activates the voltage-gated, L-type calcium channel [28] . Calcium then enters the cell, activating the contractile apparatus, leading to vasoconstriction and possibly initiating cell proliferation.
Cellular and molecular mechanisms of apoptosis in pulmonary vascular remodeling
Apoptosis, or programmed cell death, is a fundamental biological process involved in many physiological and pathological phenomena. Multicellular organisms constantly delete and renew cells to maintain their homeostasis. Dysfunction or abnormal regulation of this process has been implicated in atherosclerosis, cancer, neurodegenerative disorders, and pulmonary vascular disease [29, 30] . Death of cells in the normal turnover of tissues permits the removal of cells with genetic damage, those with improper developmental changes, or those that are produced in excess [31, 32] . At the cellular and molecular levels, apoptosis is characterized by a distinct series of morphological and biochemical changes that include cell shrinkage, formation of apoptotic bodies, caspase activation, chromatin condensation, DNA fragmentation and membrane blebbing [33] [34] [35] .
Apoptosis of vascular smooth muscle cells (VSMCs) occurs in vivo under both physiological and pathological settings. Apoptosis modulators in the vasculature are numerous and complex. Candidates may include reactive oxygen species [36] NO [37] , angiotensin type 2 (AT 2 ), receptors [38] and the endothelin system [39] . Reactive oxygen species are involved in the pathogenesis of hypertension and in apoptosis of vascular cells, where, specifically, O 2 À induces proliferation and H 2 O 2 may induce apoptosis via a protein kinase C-dependent mechanism [40] . Angiotensin (Ang) II is also a potential trigger of apoptosis [38, 41] . Ang II infusion in normotensive rats raised blood pressure and increased apoptotic rate in thoracic aortae by activation of angiotensin type 1 (AT1) and AT2 receptor subtypes [42] .
Almost all apoptotic stimuli induce the activation of some specific proteases, called caspases, which form a whole family of different cysteine-proteases cleaving target proteins at asparagine residues. Damage to DNA or to other vital molecules propagates a cascade of reaction, which activates death programs inside the cell [43, 33] [44] and other apoptosis-inducing factors from the mitochondrial intermembrane space to the cytoplasm that subsequently activates cytosolic caspases and induces apoptosis. By controlling both vascular tone and apoptosis [45] mitochondria are potentially important in the etiology and therapy of vascular disease, but their role in PAH is not known (Fig. 3) .
Several ion channels as well as transporters have been recently implicated to be involved and essential for apoptosis. This group described a strong efflux of potassium and sodium on induction of apoptosis by several stimuli, resulting in a strong decrease in the intracellular potassium concentration [46] . The role of K + channels in apoptosis was proposed by the original work of Yu et al. in 1997 [47] and subsequently supported by other investigators [48] [49] [50] . Opening of sarcolemmal K + channels increases efflux or loss of cytoplasmic K + and induces apoptotic volume decrease (AVD), whereas closure or downregulation of K + channels decelerates apoptotic cell shrinkage and attenuates apoptosis [48, 49, 51, 52, 47] .
Cell viability is governed at the molecular level by a balance between proapoptotic and antiapoptotic signals mediated by a number of gene families, the most prominent being the Bcl-2 family. Bcl-2 family members that promote cell survival include Bcl-2, A1, and the long form of Bcl-X (Bcl-X L ), whereas Bax, Bad, and Bid function to promote apoptosis. Apoptosis also require the intervention of specific sets of genes, including c-fos, c-myc, and p53-ras [53] [54] [55] [56] . The gene that causes familial primary pulmonary hypertension has been discovered to be bone morphogenetic protein receptor 2 (BMPR2) [57, 58] . The degree of apoptosis induced by these genes is critical in mediating the in vivo responses to gene therapy and the maintenance of the crucial balance between cell death and viability.
Increased elastase activity and deposition of the matrix glycoprotein tenascin-C (TN), codistributing with proliferating smooth muscle cells (SMCs), are features of pulmonary vascular disease. In organ culture studies, changes in TN expression were associated with MMP-2 and MMP-9 activity, showing that MMP-2 activity regulates TN synthesis in cultured SMCs [59] . Inhibition of MMP-2 was associated with a reduction in TN expression and onset of apoptosis [59] . Thus, there is a functional relationship between TN and MMPs, which codistribute at sites of vascular pathology [15, 16, 60] .
Role of apoptosis in development of pulmonary vascular remodeling
A considerable amount of information is known about the cellular and molecular mechanisms that control pulmonary vascular remodeling. Little attention has been given, however, to the mechanisms, which produce regression of pulmonary vascular remodeling. Apoptosis has important pathophysiological consequences contributing to the loss of pulmonary SMC and therefore in reversing the pulmonary pressure. Apoptosis eliminates unnecessary cells [61] such as cells migrated into the vascular lumen and hypertrophied cells accumulated in the pulmonary vasculature [8] .
In recent years, the process of the programmed cell death has gained much interest because of its influence on many pathological states. Increased PASMC proliferation and decreased PASMC apoptosis can concurrently mediate thickening of the pulmonary vasculature, which subsequently reduces the inner-lumen diameter of pulmonary arteries, increases pulmonary vascular resistance, and raises PAP [8, 9, 21, 62] . Results of many experiments suggest that Fig. 3 . A general model of events in apoptosis. Damage to DNA or to other vital molecules propagates a cascade of reaction, which activates death programs inside the cell, via extrinsic and intrinsic pathways. The extrinsic pathway, or the death receptor pathway, is initiated by the activation of transmembrane death receptors by the binding of proteins such as CD95, tumor necrosis factora (TNF-a), and Fas ligand. Activation of the death receptors activates the membrane proximal initiator caspase-8 (and/or caspase-10), which then cleaves procaspase-3 to generate the active effector caspase-3. Some stimuli (such as cytotoxic T cells) directly activate caspases by releasing granzymes.The intrinsic pathway, or the mitochondrial death pathway, requires disruption of the mitochondrial membrane and/or the release of cytochrome c (cyt-c) and other apoptosis-inducing factors from the mitochondrial intermembrane space to the cytoplasm that subsequently activates cytosolic caspases and induces apoptosis. Regulatory proteins of the BCL-2 family can either inhibit or promote cell death. Execution caspases (caspase-3) activate latent cytoplasmatic endonuclease and proteases that degrade cytoskeletal and nuclear proteins, which results in intracellular degradation. The end result is the formation of apoptotic bodies and consequent binding and uptaking by phagocytic cells. apoptosis play a key role in resolution of vascular remodeling [21] and clearly show that pulmonary arteries have capacity to return to normal architecture [63] . In animal experiments, it has been demonstrated that inducing apoptosis of hypertrophied PASMC in intact pulmonary vessels can prevent the progression of the medial hypertrophy [8, 63, 64] . However, other data shows that, compared with PASMCs from normal subjects and patients with SPH, PASMCs from PPH patients exhibited a significant resistance to apoptotic inducers such as BMP-2, -7, and ST [65] .
The balance between apoptosis and cell proliferation is vital for cellular homeostasis, yet little is known about the mechanisms that coordinate these two cell fates, particularly in the vessel wall. A recently identified class of cysteine proteases termed caspases coordinates the execution of the death program. Although apoptosis has long been recognized as a principal mechanism for the elimination of redundant, autoreactive, or neoplastic cells, it may also be a mechanism for the elimination of the 'misguided' proliferative PASMC in remodeled pulmonary vasculature [8] Indeed, apoptosis in hypertrophied PASMC has been attributed to regression in medial hypertrophy, whereas inhibition of apoptosis is related to progression of pulmonary vascular medial thickening [28, 64, 66] . Whether apoptosis is a growth-related compensatory mechanism or a primary process remains to be clarified. However, apoptotic cell death may also be regulated independently of cell growth.
Precise control of the balance of cell apoptosis and proliferation in PASMC plays a critical role in maintaining: (1) the normal structural and functional integrity of the pulmonary vasculature and (2) the low pulmonary arterial pressure in normal subjects. The role of apoptosis in the pulmonary vascular remodeling needs further research. The identification of biochemical markers of apoptosis and other methodological advances will ultimately help in understanding the role of apoptotic cell death in vascular remodeling and in treatment of hypertensive pulmonary disease.
Apoptosis as a therapeutic approach for patients with pulmonary hypertension
During the past few years we have witnessed tremendous advancements and have gained considerable insight in our understanding of the pathogenesis of pulmonary arterial hypertension (PAH). Several of these new insights have led to the development and clinical application of novel treatments for this devastating disease. The finding that normal vascular smooth muscle cells (VSMCs), both rat and human, undergo apoptosis in culture [67] indicates that normal VSMCs possess the machinery to undergo apoptosis. Apoptosis may be one method of regulating cell number in the vessel wall.
Although heart-lung transplantation remains the only definitive treatment for patients with advanced PAH, an antiremodeling approach to PAH treatment appears to be feasible, for several reasons. First, hypertensive pulmonary artery (PA) from patients with primary pulmonary hypertension (PPH) has been demonstrated to be actively remodeled [7] and interference with remodeling has been shown to slow or reverse the progress of the disease experimentally [68] .
Second, factors that are likely to promote remodeling, such as ACE, as well as possibly others, are present at the site of active remodeling [69] . Therefore, antiremodeling treatment may be a potential therapeutic option against various types of PAH.
Advanced pulmonary arterial hypertension is characterized by extensive vascular remodeling that is usually resistant to vasodilator therapy. There is now a shift in the interest of the scientific community, focusing on therapies aiming to reverse the proliferative remodeling in PAH [70] . The evolution of therapy from vasodilators to antiproliferative agents reflects the advancement in our understanding of the mechanisms mediating pulmonary arterial hypertension. Observations made by scientists suggest a novel strategy to treat pulmonary vascular disease by inducing regression of pulmonary vascular medial thickening, which is a pathological feature in patients with PPH and other types of severe pulmonary hypertension [8, 63, 64] . The remodeling of vascular structure, including the regression of vascular hypertrophy, is now considered a key therapeutic target in the effort to reduce mortality and morbidity associated with high blood pressure [71] [72] [73] . Inhibition of PASMC growth and augmentation of cell apoptosis could serve as therapeutic approaches for patients with pulmonary hypertension [74, 75] .
In animal models of pulmonary hypertension a variety of treatments have been used, including vasodilators [76, 77] anticoagulant agents [78] and lung or heart-lung transplantation [79, 80] but none have resulted in improved survival in a prospective, randomized trial. Several antihypertensive drugs currently used in therapy may exert their pharmacological effects by promoting SMC apoptosis [81] . However, it has been difficult to manipulate apoptosis in vivo, because most drugs targeting intracellular signaling events involved in apoptosis are not very well membrane permeable. Ion channels with their extracellular domain might be very attractive targets for the development of drugs preventing or inducing apoptosis, because they can be easily reached and modified in the extracellular compartment [81] .
Effective therapies must promote from proliferation to apoptosis. We here summarize the relatively small number of most recent studies with different therapeutic alternatives available in the PAH by inducing apoptosis chiefly of PSMSc. We provide specific examples of how modulation of the apoptotic process contributes to pulmonary arterial medial hypertrophy regression. The sporadic promotion of apoptosis may require multiple therapeutic strategies deployed to numerous apoptotic targets.
Survivin
Survivin (also termed Birc5) belongs to the family of genes known as inhibitors of apoptosis, and it has been implicated in both prevention of cell death and control of mitosis. McMurtry et al. reported that adenovirus-mediated overexpression of survivin -a multipotent inhibitor of apoptosis -induces PAH in rats, whereas inhalation of an adenovirus vector encoding a mutant survivin gene with dominant-negative properties reverses established monocrotaline-induced PAH [82] . Survivin is a critical regulator of SMC apoptosis. These findings raise important issues regarding the role of survivin in the pathogenesis of PAH, its value as a prognostic indicator, and its use as a target for new therapeutic strategies [83] . The use of molecular antagonists of survivin to increase cell death and to prevent pathological vascular remodeling might hold therapeutic potential [84] .
3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors: mevastatin and simvastatin
Compounds with antiproliferative effects on vascular endothelial and smooth muscle cells, such as 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (mevastatin and simvastatin), can prevent the development of experimental hypertensive pulmonary vascular disease [85, 86] . Mevastatin can both inhibit cell proliferation and induce apoptosis in PASMCs through p27
Kip1 -independent pathways and may be important therapeutic agents in pulmonary arterial hypertension [87] .
Simvastatin attenuates monocrotaline-induced pulmonary vascular remodeling with neointimal formation, pulmonary arterial hypertension, and right ventricular hypertrophy in rats. Simvastatin increased apoptosis of pathological smooth muscle cells in the neointima and medial walls of pulmonary arteries. Longitudinal transcriptional profiling revealed that simvastatin downregulated the inflammatory genes fos, jun, and tumor necrosis factor-alpha and upregulated the cell cycle inhibitor p27Kip1, endothelial nitric oxide synthase, and bone morphogenetic protein receptor type. Thus, simvastatin reverses pulmonary arterial neointimal formation and PAH by inducing apoptosis of neointimal smooth muscle cells [88] .
Apoptosis signal-regulating kinase 1 (ASK1)
ASK1 has been identified as an apoptosis-inducing kinase [89] and recently has also reported to be implicated in a variety of cellular functions. ASK1 plays a critical role in vascular remodeling. Researches obtained the evidence that ASK1 directly participates in VSMC proliferation and migration and neointimal thickening in injured artery. Of note are the observations that gene transfer of DN-ASK1 significantly prevented neointimal hyperplasia as shown by the I/M ratio and suppressed VSMC proliferation in either the intima or the media. ASK1 may provide the basis for the development of new therapeutic strategy for vascular diseases [90] .
Peroxisome proliferator-activated receptor gamma (PPARgamma)
Peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear hormone receptor superfamily, which regulates transcription of target genes in a ligand-dependent manner. Ligands for PPARgamma have been shown to attenuate proliferation of vascular smooth muscle cells, and to induce apoptosis in several cell lines in vitro. PPARgamma ligands reduce MCT-induced pulmonary hypertension and pulmonary vascular wall thickening in rats. Inhibition of MCT-induced cell proliferation and induction of apoptosis in the pulmonary arterial walls may account for this effect [91] .
Bradykinin receptor agonists
Bradykinin is an important modulator of endothelial cell function and has also a powerful cardioprotective effect. Taraseviciene-Stewart et al. have reported that treatment of severely pulmonary hypertensive rats with a newly synthesized long-acting bradykinin B2 receptor agonist B9972 caused reduction of the pulmonary artery pressure and of right ventricular hypertrophy. Treatment with B9972 decreased the number of plexiform lesions in the lungs by inducing cell apoptosis in the obliterated vessels [92] .
Dichloroacetate (DCA)
Mitochondria control apoptosis and produce activated oxygen species like H 2 O 2 , which regulate vascular tone by activating K + channels, but their role in PAH is unknown. Dichloroacetate (DCA), a metabolic modulator that increases mitochondrial oxidative phosphorylation, prevents and reverses established monocrotaline-induced PAH (MCT-PAH), significantly improving mortality. DCA depolarizes MCT-PAH PASMC mitochondria and causes release of H 2 O 2 and cytochrome c, inducing a 10-fold increase in apoptosis within the PA media and decreasing proliferation. Thus mitochondria-dependent apoptosis is a potential target for therapy and DCA as an effective and selective treatment for PAH [93] .
Elastase inhibitors
Administration of elastase inhibitors reverses fatal pulmonary arterial hypertension (PAH) in rats by inducing smooth muscle cell (SMC) apoptosis. In pulmonary artery (PA) organ culture the mechanism by which elastase inhibitors induce SMC apoptosis involves repression of matrix metalloproteinase (MMP) activity and subsequent signaling through alphavbeta3-integrins and epidermal growth factor receptors (EGFRs). This suggests that blockade of these downstream effectors may also induce regression of PAH. Selective blockade of EGFR signaling may be a novel strategy to reverse progressive, fatal PAH [94] .
Rho/Rho-associated kinase (Rho-kinase) system
The Rho/Rho-associated kinase (Rho-kinase) system is implicated in various cellular functions, including migration, proliferation, and apoptosis. Specific Rho-kinase inhibitor, Y27632, inhibited early neointimal lesion formation, by suppressing early SMC migration into the intima and prevented neointima formation in the later phase by enhancing neointimal SMC apoptosis [95] . Kohtaro Abe et al. found that long-term blockade of Rho-kinase with fasudil, which is metabolized to a specific Rho-kinase inhibitor hydroxyfasudil after oral administration, markedly improved survival when started concomitantly with monocrotaline and even when started after development of pulmonary hypertension. The fasudil treatment improved pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular lesions with suppression of VSMC proliferation and macrophage infiltration, enhanced VSMC apoptosis, and amelioration of endothelial dysfunction and VSMC hypercontraction [96] .
These findings indicated that the Rho-kinase-mediated pathway is substantially involved in the MCT-induced PH and that the long-term inhibition of Rho-kinase prevents or even causes a marked improvement of the MCT-induced PH through multiple mechanisms, including: (1) inhibition of VSMC proliferation with enhanced apoptosis, (2) reduced macrophage infiltration, and (3) improvement of endothelium-dependent relaxation and VSMC hypercontraction.
Conclusions
Apoptotic death of vascular smooth muscle cells (SMCs) is a prominent feature of blood vessel remodeling. The net balance between proliferation and apoptosis determines the extent of SMC growth. Taken together shown in this study, we speculate that inhibition of apoptosis in PASMCs is involved in the development and progression of pulmonary arterial medial hypertrophy, whereas induction or enhancement of PASMC apoptosis may be targeted to develop therapeutic approaches for pulmonary vascular remodeling in patients with PAH. SMC apoptosis may be a selective target for pharmacological intervention in hypertension. Understanding the apoptotic process, which appears as complex and highly regulated as that of proliferation, may yield valuable information in treatment of these diseases. An alteration in thresholds for apoptosis is becoming prominent concepts as we move along in our quest to understand and ultimately treat this disease.
